Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 25

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 25
---
 failure to maintain supply of compliant, quality medicines;

- the risk of illegal trade in the Group's medicines;

- the impact of reliance on third-party goods and services;

- the risk of failure in information technology or cybersecurity;

- the risk of failure of critical processes;

- the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives;

- the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce;

- the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment;

- the risk of the safety and efficacy of marketed medicines being questioned;

- the risk of adverse outcome of litigation and/or governmental investigations;

- intellectual property risks related to the Group's products;

- the risk of failure to achieve strategic plans or meet targets or expectations;

- the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business;

- the risk of failure in internal control, financial reporting or the occurrence of fraud; and

- the risk of unexpected deterioration in the Group's financial position.

Glossary

1L, 2L, etc first line, second line, etc

aHUS Atypical haemolytic uraemic syndrome

BCG Bacillus Calmette-Guérin therapy

BRCA / m Breast cancer gene / mutation

BTC Biliary tract cancer

BTKi Bruton tyrosine kinase inhibitor

CER Constant exchange rates

CHMP Committee for Medicinal Products for Human Use (EU)

CI Confidence interval

CKD Chronic kidney disease

CLL Chronic lymphocytic leukaemia

CN China

COPD Chronic obstructive pulmonary disease

CRSwNP Chronic rhinosinusitis with nasal polyps

CTx Chemotherapy

CVRM Cardiovascular, Renal and Metabolism

EBITDA Earnings before interest, tax, depreciation and amortisation

EGFR / m Epidermal growth factor receptor gene / mutation

EGPA Eosinophilic granulomatosis with polyangiitis

EPS Earnings per share

ESC European Society of Cardiology

ESMO European Society for Medical Oncology

EVH Extravascular haemolysis

FDC Fixed dose combination

FLOT Fluorouracil, oxaliplatin and docetaxel

GEJ Gastro oesophageal junction

GI Gastrointestinal

GLP-1 glucagon-like peptide-1 receptor

gMG General